
Supernus expands its portfolio of Parkinson's drugs with a $400M+ buyout
Supernus is marking its expansion into the Parkinson’s disease arena, striking a deal to buy out Adamas Pharmaceuticals in a deal worth more than $400 million.
A year after swooping in on its first Parkinson’s acquisition, the two companies announced that they had reached an agreement for Supernus to pay up to $9.10 per share in cash as part of the acquisition — close to $450 million.
“This acquisition represents a significant step to further build a strong and diverse Parkinson’s disease portfolio, and aligns with our focus of acquiring value-enhancing, clinically-differentiated medicines to treat CNS diseases,” said Supernus CEO Jack Khattar in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.